We recently published on the effect of a combination treatment of DMR and glucagon-like peptide-1 receptor agonist (GLP-1RA) administration in a pilot study of 16 patients with T2DM, treated with insulin and found an overall improvement in glycaemic and metabolic endpoints, leading to a discontinuation of insulin treatment in 69% of the patients at 6 months. This evidence concerns the gene INS and type 2 diabetes mellitus.